Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics, Ltd, a joint venture. The company will focus on novel approaches to inducing a state of ketosis, which may have protective effects against age-related disease.
“There is substantial evidence to support the hypothesis that ketogenesis plays a role in preventative medicine,” said Eric Verdin, MD, President and CEO of the Buck Institute.”We are delighted to be building on our existing relationship with Juvenescence in this new venture.”
BHB Therapeutics is based on research conducted in the labs of Eric Verdin, MD and John Newman, MD, PhD. The work centers on the emerging signalling functions of a metabolite created by the body during fasting or exercise, the ketone body beta-hydroxybutyrate (BHB). They have discovered that BHB helps the body respond to stresses, and that long-term exposure to ketone bodies using a ketogenic diet can extend healthy lifespan in model systems. “I am pleased to start this journey to turn exciting science into therapies that help improve and maintain health throughout our lifespan,” said Buck Professor Newman.
“Juvenescence is focused on developing and commercializing products that have strong evidence of providing material benefit to an aging population. We believe that some of the compounds identified by Dr. Verdin and Dr. Newman have unique qualities that could provide real benefit,” said Gregory Bailey, MD, the CEO of Juvenescence. “Most Juvenescence therapies will follow a traditional regulatory pathway. We are excited by the prospect of working with scientists at the Buck to bring these compounds to people in the near term.”
Commenting on the announcement, Founder and Chairman of Juvenescence and Buck Board Member Jim Mellon said that “preventative medicine is a key element of the health strategy required to treat aging effectively. We believe that this project has the potential to help extend people’s healthspan.”